Abstract
Antioxidant resveratrol showed nephron protective effects in different experimental models. However, human data are limited. Beneficial effects of resveratrol in patients with IgA nephropathy as suggested by in silico drug screening have not been evaluated. Our objective was to investigate the effect of resveratrol treatment on oxidative stress, renal function and albuminuria in IgA nephropathy patients. Twenty-seven IgAN patients were randomized to receive either resveratrol (2 x 5 mg/day) or placebo for 12 weeks, and were followed-up for additional 12 weeks. Male IgA nephropathy patients exerted initially higher urinary ortho-tyrosine concentration than females, indicative of increased oxidative stress, which may explain their worse prognosis. We noted that resveratrol treatment reduced urinary ortho-tyrosine excretion after 6 weeks, while it increased glomerular filtration rate and albuminuria in male but not in female IgA nephropathy patients. Due to these adverse effects our study was earlier terminated. Statin therapy had no impact on CCL11 or the anti-aging alpha-Klotho levels. In conclusion, increased glomerular filtration rate and albuminuria with resveratrol treatment could be resulted from hyperfiltration of the residual nephrons that occurred also after bardoxolone methyl administration in diabetic renal patients, and thus may negatively affect kidney function long-term.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have